Combination Antiviral Therapy Improves Survival in HHV-6B Encephalitis Post-Cord Blood Transplant

Background

Human herpesvirus-6B (HHV-6B) encephalitis is a severe complication following cord blood transplantation (CBT), with a reported incidence of 7.5% in this study. The disease carries high mortality and morbidity, yet optimal antiviral management remains controversial. This registry-based study from Japan provides critical real-world evidence on the impact of different antiviral regimens—foscarnet (FCN) monotherapy, ganciclovir (GCV) monotherapy, and FCN/GCV combination therapy—on survival outcomes.

Study Design